



# Immunization Program Provider

## Update: COVID-19 vaccine for 6 months through 4/5 years

**06/21/2022**

Merideth Plumpton, RN - *Nurse Program Coordinator*

Meghan Knowles – *Provider Communication and Training Coordinator*

# Agenda – 06/21/2022

Slides and recording will be posted by end of the day at [www.healthvermont.gov/COVID19-vaccine-healthpros#resources](http://www.healthvermont.gov/COVID19-vaccine-healthpros#resources)

## COVID-19 for 6 months through 4/5 years

- ACIP recommended schedule
- Vermont implementation
- Ordering guidance
- Storage and handling
- Administration
- Resources

## Other COVID-19 vaccine information

- Moderna for 6 through 17 years
- Janssen vaccine
- Novavax


## Contact Information

- Ordering, vaccine storage and handling, vaccine-specific information:  
[AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov)
- Immunization registry and reporting questions:  
[IMR@vermont.gov](mailto:IMR@vermont.gov)
- Program updates available on the Vaccine Information for Health Care Professionals Page:  
[www.healthvermont.gov/disease-control/immunization-providers#vvpupdate](http://www.healthvermont.gov/disease-control/immunization-providers#vvpupdate)

# **ACIP Recommendations**

**Merideth Plumpton – Nurse Program Manager**

# COVID-19 Vaccine Approval Process




# ACIP Pediatric COVID-19 Vaccine Updates

- June 18, 2022 ACIP Interim Clinical Considerations Update for Pediatric COVID-19 Vaccine slide deck: [www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-17-18/04-COVID-Hall-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-06-17-18/04-COVID-Hall-508.pdf)
- Interim Clinical Considerations: [www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html)
- At-A-Glance COVID-19 Vaccination Schedule: [www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf](https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf)

# Pediatric Schedule: Pfizer-BioNTech COVID-19 Vaccine


People who are **NOT** moderately or severely immunocompromised

**Pfizer-  
BioNTech**  
(6 months–  
4 years)



People who **ARE** moderately or severely immunocompromised

**Pfizer-  
BioNTech**  
(6 months–  
4 years)



# Pediatric Schedule: Moderna COVID-19 Vaccine

People who are **NOT** moderately or severely immunocompromised

---

**Moderna**  
(6 months–  
5 years)

## Primary Series



People who **ARE** moderately or severely immunocompromised

---

**Moderna**  
(6 months–  
5 years)

## Primary Series



# Considerations for Extended Intervals

## Longer Interval

- Studies have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. Extending the interval beyond 8 weeks has not been shown to provide additional benefit.

An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 5-64 years, especially for males ages 12–39 years.

## Shorter Interval:

- Immunocompromised
- Are at high-risk for severe disease, or live with others who are
- High community levels




# Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised


**Pfizer-BioNTech**  
(6 months–  
4 years)



**Pfizer-BioNTech**  
(5–17 years)



**Moderna**  
(6 months–  
5 years)



# Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised


**Pfizer-BioNTech**  
(6 months–  
4 years)



**Pfizer-BioNTech**  
(5–11 years)



**Pfizer-BioNTech**  
(12–17 years)



**Moderna**  
(6 months–  
5 years)




# Vermont Implementation

**Merideth Plumpton – Nurse Program Manager**

# COVID-19 vaccine for those 6 months through 5 years - Vermont implementation

~26,000 total patients are newly eligible (6 months through 4 years old)

- Medical homes will be the primary vaccinators
- Pharmacies can only vaccinate age 3 and older, and few are participating for these ages
- Community walk-in clinics are limited. Information can be found on the [Getting the COVID-19 Vaccine](#) webpage.
- Offices of Local Health will focus on vaccinating WIC participants and equity clinics. WIC families accounts for ~8,000 individuals in this age range.



## Follow-up with provider offices

Normalize the COVID-19 vaccine.

- If you offer other state supplied vaccines, you should be offering COVID-19 as well. The Immunization Program is here to help if you find this challenging.
- COVID-19 vaccine should be a part of your conversations with patients, the same as you would offer Flu or other indicated vaccines.
- If you are not offering the COVID-19 vaccine, you should be aware of other opportunities in your community and assist patients with access.

Outreach has been ongoing with Vermont health care providers. We will be contacting offices who indicated they were planning to serve their youngest populations but did not order any vaccine in June.

# Ordering Guidance


**Meghan Knowles – Provider Communication and Training**

# Starting June 27, order what you need

- Expect plenty of supply. Check VIMS to confirm approved order quantity and delivery type.
- March Immunization Program Training covers specifics on ordering
  - [Video: www.youtube.com/watch?v=y9msC5c8d4s](https://www.youtube.com/watch?v=y9msC5c8d4s)
  - [Slides: Immunization Program COVID-19 Vaccine Training](#)
  - [COVID-19 Ordering Guidance](#) Resource
- [Order Status and Shipment Tracking](#)

# General Ordering Reminders

- You can place your COVID-19 orders anytime you need, but should plan to order around the monthly reconciliation of your inventory
- Track and document all wasted vaccine – It is expected and ok!
  - Opened vial = No eligible person
  - Unopened vial = Expired
  - No Returns



The image shows a screenshot of a web-based form for tracking vaccine waste. At the top, there are four input fields: a dropdown menu with 'Waste' selected, a dropdown menu with 'COVID: No E' selected, a dropdown menu with an empty selection, and a text box containing the number '3'. Below these fields, there are two buttons labeled 'Delete' and 'Cancel'. A dropdown menu is open, displaying a list of reasons for vaccine waste. The first three items in the list are highlighted in yellow: 'Broken Vial / Syringe', 'COVID: expired - unopened multi-dose vial', and 'COVID: No Eligible Person'. The remaining items are 'Improper Storage - Wastage', 'Open MDV - Temp Excursion', 'Open MDV / Expired', 'Open MDV / Expired - Transferred, not used', 'Unable to obtain all doses from multi-dose vial', and 'Vaccine Drawn / Not Given'.

Waste	COVID: No E		3
Broken Vial / Syringe	COVID: expired - unopened multi-dose vial	COVID: No Eligible Person	
Improper Storage - Wastage			
Open MDV - Temp Excursion			
Open MDV / Expired			
Open MDV / Expired - Transferred, not used			
Unable to obtain all doses from multi-dose vial			
Vaccine Drawn / Not Given			



# Storage and Handling

**Meghan Knowles – Provider Communication and Training**

# Accepting Deliveries

## Depot Deliveries

### Pfizer + Moderna

- Will come refrigerated, place in state monitored refrigerator
- DO NOT REFREEZE
- BUD will be on delivery. Label all vaccine clearly.



## Direct Shipments

### Pfizer

- Will come frozen, place in state monitored refrigerator unless UTC storage (-90 C to -60 C) is available
- **DO NOT PLACE IN STANDARD FREEZER**
- BUD based on when vaccine enters refrigerator. Label all vaccine clearly.

### Moderna

- Will come frozen. Place in state monitored Refrigerator OR Freezer
  - Refrigerator: BUD based on when vaccine enters unit. Label all vaccine clearly
  - Freezer: No BUD. Vaccine good through expiration

# Moderna Direct Deliveries – Return of Shippers

## Moderna COVID-19 Vaccine Inside at -20°C **IMPORTANT:** DO NOT PLACE VACCINE ON DRY ICE



### RECEIVING AND UNPACKING STEPS

- 1 IMMEDIATELY** open the cooler and follow the TagAlert receiver instructions. See below for details.
- 2 Compare** the packing list to the contents of the cooler to confirm they match. See back for details.
- 3 Inspect** the vaccine and report any tampering (i.e., broken seal). See back for details.
- 4 Place vaccine** in appropriate storage immediately upon receipt.
- 5 Repack** the cooler to return. See back for details.
- 6 Return** cooler with regular UPS delivery person or call 1-800-PICK-UPS to schedule a pickup. See back for details.




- Remove vaccine and put all packing/cooling items back in the box
- Return label is included on the INSIDE flap. Fill it out and tape box up as the outside flap.
- Contact UPS for pick-up.

# Pfizer Direct Deliveries – Return of Temperature Device

## Pfizer




- A few types of Pfizer shippers are available. Some may ask to be returned.
- All will ask to at least return the temperature device. Instructions will be included.



# Pfizer Storage

**EUAS**  
[Pfizer-BioNTech, maroon cap \(6m - 4 years\)](#)  
  
[Pfizer-BioNTech, orange cap \(5 - 11 years\)](#)  
  
[Pfizer-BioNTech, gray cap \(12+ years\)](#)

**Quick Guide**  
[formulation-guide \(pfizer.com\)](#)

Description	Do Not Dilute	Dilute Before Use	Dilute Before Use
Age Group	12 years and older	5 through 11 years	6 mos through 4 years <sup>1</sup>
Vial Cap Color and Label with Color Border	GRAY 	ORANGE 	MAROON 
Storage Conditions			
ULT Freezer (-90°C to -60°C)	12 months**	12 months**	12 months**
Freezer (-25°C to -15°C)	DO NOT STORE	DO NOT STORE	DO NOT STORE
Refrigerator (2°C to 8°C)	10 weeks	10 weeks	10 weeks
Room Temperature (8°C to 25°C)	12 hours prior to first puncture (including any thaw time)	12 hours prior to dilution (including any thaw time)	12 hours prior to dilution (including any thaw time)
After First Puncture (2°C to 25°C)	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours


Doses/vial	6 – do not dilute	10 after dilution	10 after dilution
Min for Direct shipment	300 doses/50 vials	100 doses/10 vials	100 doses/10 vials <sub>21</sub>



# Pfizer Labeling– Many Errors

## Pfizer-BioNTech COVID-19 Vaccine Formulation for Ages 6 Months–4 Years

Vaccine may be discarded **12 hours** after dilution rather than **6 hours**.



Vial label states Age 2y to <5y but can be used in children ages 6 months–4 years.

# Pfizer Training

Pfizer Vaccines US Medical Affairs hosts **daily** Medical Updates & Immunization Site Training for All Healthcare Providers.

In addition to medical updates, sessions will focus on vaccine storage, handling, and administration of vaccines all three vaccine formulations.

These sessions will be updated to reflect new information and changes that evolve. Updates will be identified at the start of each session and explained during each presentation.

For a list of training sessions, including links and instructions for registration, visit the [Pfizer training website](https://www.pfizermedicalinformation.com/en-us/medical-updates) - <https://www.pfizermedicalinformation.com/en-us/medical-updates>

# Moderna Storage

Magenta  
border



Blue  
border



**Formulation for ages  
6 months–5 years**



**Formulation for ages  
12 years and older**

## EUAS

[Moderna, magenta border  
\(6m – 5 years\)](#)

[Moderna, light blue border  
\(12+ years\)](#)

Note: this formulation is currently only approved for 18+ and may not be administered to those 12-17 years.

Vial cap color	Dark blue	Red
Label border color	Magenta	Light blue
<b>Storage Conditions</b>		
<b>ULT Freezer (-90°C to -60°C)</b>	N/A	
<b>Freezer (-25°C to -15°C)</b>	<b>Viable through Expiration: Do not Refreeze</b>	
<b>Refrigerator (2°C to 8°C)</b>	30 days	
<b>Room Temperature (8°C to 25°C)</b>	24 hours prior to first puncture (including thaw time)	
<b>After First Puncture (2°C to 25°C)</b>	Discard after 12 hours	

**Doses/vial**

**Min for Direct shipment**


**10 – do not dilute**

**100 doses/10 vials**




# Moderna Labeling

## Moderna COVID-19 Vaccine Formulation for Ages 6 Months Through 5 Years



703819



STORE FROZEN between  
-50° to -15°C (-58° to 5°F).  
Protect from light. No preservative.  
After first use, hold at 2° to 25°C  
(36° to 77°F). Discard after 12 hours.

Record date/time of first use: \_\_\_\_\_


Scan here for FDA-authorized Fact Sheet  
for dosage and administration,  
and product expiration dates, or visit  
[www.modernatx.com/covid19vaccine-eua/](http://www.modernatx.com/covid19vaccine-eua/)

Mfd. for: Moderna US, Inc.,  
Cambridge, MA 02139

**Moderna  
COVID-19  
Vaccine**

Suspension for  
Intramuscular Injection  
For use under  
Emergency Use Authorization

**Age 6mo through 5y**


 Vial contains  
10 doses of 0.25 mL

NDC 80777-279-05

LOT

# Develop a System That Works for You

- Color coded labeling, bins, and binders
- Make specific people responsible for tracking BUD. Have it written into their job duties and give them appropriate time.
- Everyone administering is responsible to understand BUD and storage limitations. Keep each other accountable. Double/triple checks.



FORMULATION: 5 Through 11 Years of Age  
**Pfizer-BioNTech COVID-19 Vaccine**

Store vaccine between 2°C and 8°C (36°F and 46°F) for up to 10 weeks.

Lot number(s): 123456A


Today's date: 06 / 01 / 2021 Time: 2:30 PM

**USE BY\***

Date: 08 / 10 / 2021 Time: 2:30 PM

\*As the 10 week deadline approaches, contact the manufacturer for guidance if you will not be able to use the vaccine.

Name: Amy Nurse RN



[CDC's COVID-19 Vaccine Product Information](#) webpage has BUD labels and guidance.

## When an issue is found...

- Always contact the main inbox or call the main line. Do not contact an individual for anything time sensitive.
  - [AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov)
  - 802-863-7638

# Storage and Handling Resources

VDH Resources:

[Receipt and Management of COVID-19 Vaccine](#)

[COVID-19 Vaccine Expiration Date and BUD Guidance](#)

[Vaccine Carrier Borrowing Program](#)

[Vaccine Storage and Handling for Off-site Clinic Guidance](#)

[Temperature Excursion Protocol](#)

CDC/Manufacturer Resources: [U.S. COVID-19 Vaccine Product Information | CDC](#)

# Administration

**Merideth Plumpton – Nurse Program Manager**

# Moderna COVID-19 Vaccine Formulations



**Formulation for ages  
6 months–5 years**



**Formulation for ages  
12 years and older**

Authorized for ages	6 months–5 years	12 years and older
Vial cap color	Dark blue	Red
Label border color	Magenta	Light blue
Dose (mRNA concentration)	25 mcg	100 mcg
Injection volume	0.25 mL	0.5 mL
Dilution required	No	No
Doses per vial	10	Maximum of 11

# Pfizer-BioNTech COVID-19 Vaccine Formulations



**Formulation for  
ages 6 months–  
4 years**



**Formulation for  
ages 5–11 years**



**Formulation for  
ages 12 years  
and older**

Authorized for ages	6 months–4 years	5–11 years	12 years and older
Vial cap color	Maroon	Orange	Gray
Dose (mRNA concentration)	3 mcg	10 mcg	30 mcg
Injection volume	0.2 mL	0.2 mL	0.3 mL
Dilution required	Yes—2.2 mL	Yes—1.3 mL	No
Doses per vial	10 (after dilution)	10 (after dilution)	6

## Transitioning from a younger to older age group


People should receive the recommended age-appropriate vaccine dosage based on their age on the day of vaccination. If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability:~:text=People%20should%20receive,all%20subsequent%20doses>




# Pfizer Only

**Scenario 1:** A 2-dose primary series using the formulation for people ages 5–11 years (orange cap)



**Scenario 2:** A 3-dose primary series initiated with the formulation for ages 6 months–4 years. Dose 2 and 3 may be with: the formulation for ages 6 months–4 years or the formulation for ages 6–11 years.



# Interchangeability

- COVID-19 vaccines are not interchangeable.
- The same mRNA vaccine product should be used for all doses of the primary series.
- In exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, either age-appropriate available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.

# Administration

<b>Intramuscular (IM) injection</b> Use a 22–25 gauge needle. Choose the injection site and needle length that is appropriate to the person's age and body mass.		
<b>AGE</b>	<b>NEEDLE LENGTH</b>	<b>INJECTION SITE</b>
Infants (1–12 mos)	1"	Anterolateral thigh muscle
Toddlers (1–2 years)	1–1¼"	Anterolateral thigh muscle <sup>2</sup>
	5/8–1" <sup>1</sup>	Deltoid muscle of arm
Children (3–10 years)	5/8–1" <sup>1</sup>	Deltoid muscle of arm <sup>2</sup>
	1–1¼"	Anterolateral thigh muscle

<sup>1</sup> A 5/8" needle may be used in newborns, preterm infants, and patients weighing less than 130 lbs (<60 kg) for IM injection in the deltoid muscle only if the skin stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle to the skin.

<sup>2</sup> Preferred site

[Administering Vaccines: Dose, Route, Site, and Needle Size \(immunize.org\)](https://immunize.org)

# Coadministration of COVID Vaccines and Routine Vaccines

COVID-19 vaccines may be administered without regard to timing of other vaccines. This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day.

[www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability:~:text=Coadministration%20of%20COVID%2D19%20vaccines%20with%20other%20vaccines](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability:~:text=Coadministration%20of%20COVID%2D19%20vaccines%20with%20other%20vaccines)

# COVID-19 Vaccine Administration Errors

Error	Recommended Action
<ul style="list-style-type: none"><li>If the incorrect formulation is administered, resulting in a <b>higher -than-authorized dose</b></li></ul>	<ul style="list-style-type: none"><li>Do <b>NOT</b> repeat dose.<sup>†‡</sup></li></ul>
<ul style="list-style-type: none"><li>If the incorrect formulation is administered, resulting in a <b>lower -than-authorized dose</b></li></ul>	<ul style="list-style-type: none"><li>Repeat dose immediately (no minimum interval) with the age-appropriate formulation.</li><li>Some experts suggest delaying the repeat dose for 8 weeks after the invalid dose based on the potential for increased reactogenicity and the rare risk of myocarditis from mRNA COVID-19 vaccine, especially in males ages 12–39.<sup>†‡</sup></li></ul>

<sup>†</sup>If the administration error resulted in a higher-than-authorized vaccine dose, in general a subsequent dose may still be administered at the recommended interval. However, if local or systemic side effects following vaccination are clinically concerning (outside of the expected side effect profile), lead to serious adverse reactions, or are ongoing at the time of the subsequent dose, this dose might be delayed, but this decision should be assessed on a case-by-case basis.

<sup>‡</sup>If the dosing is in accordance with the FDA EUA, it is not considered an error and VAERS reporting is not indicated.

<https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#timing-spacing-interchangeability:~:text=Appendix%20C.%20Vaccine%20administration%20errors%20and%20deviations>

# Fully Vaccinated vs. Up to Date

- CDC recommends COVID-19 primary series vaccines for everyone ages 6 months and older, and COVID-19 boosters for everyone ages 5 years and older, if eligible.
- People who are moderately or severely immunocompromised have specific recommendations for COVID-19 vaccines, including boosters. Learn more about [COVID-19 vaccine recommendations for people who are moderately or severely immunocompromised](#).
- Use [CDC's COVID-19 booster tool](#) to learn if and when you can get boosters to stay up to date with your COVID-19 vaccines.
- The following [COVID-19 vaccine and booster recommendations](#) may be updated as CDC continues to use the latest data related to safety and how well vaccines work, including over time and against new variants.

[Stay Up to Date with Your COVID-19 Vaccines | CDC](#)



# v-safe



The top section of the banner features four vertical colored bars: green with a white bandage icon, blue with a white smartphone icon displaying the v-safe logo, purple with a white thumbs-up icon, and a large blue and green chevron graphic. To the right of these bars, the text "v-safe<sup>SM</sup> after vaccination health checker" is displayed in black.



A circular inset image shows a smiling family of four (a man, a woman, and two children) holding a smartphone that displays the v-safe app interface.

**NEW!** | People who have already been vaccinated can enter an additional dose.  
Parents or guardians can enroll their vaccinated children.

323388-AH

Get vaccinated. Get your smartphone. Get started with v-safe.

Use your smartphone to tell CDC how you, or your dependent, feel after getting any dose of the COVID-19 vaccine. Your participation in **v-safe** helps us monitor the safety of COVID-19 vaccines for everyone.

[v-safe print resources](#)

# Observation Period

CDC recommends the following observation periods after COVID-19 vaccination:

- **30 minutes:**

- People with a contraindication to a different type of COVID-19 vaccine.
- History of non-severe, immediate (onset within 4 hours) allergic reaction after a previous dose of COVID-19 vaccine.
- History of an immediate allergic reaction of any severity to non-COVID-19 vaccines or injectable therapies.
- History of anaphylaxis due to any cause.

- **15 minutes:** All other people



# Ancillary Supplies (Pfizer)

- Purchased by the US Government and distributed by McKesson at the direction of the US Government
- Vaccination sites will receive supplies for appropriate pack size shipment
- Upon receipt of the ancillary kit, take inventory to confirm all necessary components are present and in correct ratios

Gray Cap	Orange Cap	Maroon Cap
<ul style="list-style-type: none"><li>• Needles (22-25G X 1")</li><li>• Needles (22-25G X 1.5")</li><li>• Syringes (1 mL)</li><li>• Alcohol pads</li><li>• Vaccination record cards</li><li>• Needle gauge and length charts</li><li>• Face shields</li><li>• Surgical masks</li></ul>	<ul style="list-style-type: none"><li>• Needles (25G X 1")</li><li>• Mixing needles (21-25g x1.5")</li><li>• Syringes (1 mL)</li><li>• Syringes (3 mL or 5 mL)</li><li>• Alcohol pads</li><li>• Vaccination record cards</li><li>• Needle gauge and length charts</li><li>• Face shields</li><li>• Surgical masks</li><li>• Diluent vials (10 mL)</li></ul>	<ul style="list-style-type: none"><li>• Needles (25G X 1")</li><li>• Mixing needles (21-25g x1.5")</li><li>• Syringes (1 mL)</li><li>• Syringes (3 mL or 5 mL)</li><li>• Alcohol pads</li><li>• Vaccination record cards</li><li>• Needle gauge and length charts</li><li>• Face shields</li><li>• Surgical masks</li><li>• Diluent vials (10 mL)</li></ul>

## Ancillary Supplies (Moderna)

An ancillary kit with supplies will be provided for administering the vaccine.

Administration supplies include needles, syringes, sterile alcohol prep pads, vaccination record cards (shot cards), and some PPE.

The kit is delivered separately from the vaccine. Unpack the kit and check for receipt of the correct administration supplies and quantities.

# **Moderna for 6 – 17 years**

**Merideth Plumpton – Nurse Program Manager**

## Moderna ages 6 through 11, and 12 through 17

On June 14, 2022, VRBPAC recommended authorization of Moderna COVID-19 vaccine 2-dose series for children 6-11 years and 12-17 years. **ACIP will meet on June 22 and 23.**

**No Moderna vaccine should be given to children 6 through 17 years until CDC provides a recommendation.**

- Data on a 3rd dose for both groups is likely to be submitted to the FDA for consideration in mid-July 2022.
- Moderna 12-17 years (100mg): Same formulation as current 18+ formulation. Once approved, the current product (Red Cap, Blue Label) may be used for 12+.
- Moderna 6-11 years (50mg) will be a new product with a unique NDC.

# **Janssen and Novavax**

**Merideth Plumpton – Nurse Program Manager**

# FDA Limits use of Janssen COVID Vaccine

- May 5<sup>th</sup>, FDA limited use of Janssen COVID-19 vaccine to those 18 and older for whom other vaccines are not accessible or clinically appropriate, or those who choose to receive Janssen because they would otherwise not get vaccinated. FDA cited the risk of rare but potentially life-threatening blood clots.
- CDC talking about sunseting Janssen COVID vaccine when doses run out

[FDA Press Release](#)

[Fact Sheet for Healthcare Providers Administering Vaccine](#)

# Novavax COVID Vaccine

- VRBPAC approved Novavax COVID vaccine on 6/7
- Ongoing discussions about this vaccine product being made available in the US this fall
- Not in current CDC contract to purchase any doses
- Will want a non mRNA option once Janssen is no longer available

# Questions?

- Q+A from the chat will be sent by e-mail along with the recording and slide deck.
- Recording of this and past trainings are available on the [Vaccine Information for Health Care Professionals](#) website.
- Direct all COVID-19 vaccine questions to [AHS.VDHImmunizationProgram@vermont.gov](mailto:AHS.VDHImmunizationProgram@vermont.gov).



# Resources

**Meghan Knowles – Provider Communication and Training**

## Other training

- [COVID-19 Vaccine Training Modules](#) | CDC:



### COVID-19 Vaccine Training Modules

-  [COVID-19 Vaccine Training: General Overview of Immunization Best Practices for Healthcare Providers](#) (Updated October 27, 2021)
-  [Janssen COVID-19 Vaccine \(Johnson & Johnson\): What Healthcare Professionals Need to Know](#) (Updated March 8, 2022)
-  [Moderna COVID-19 Vaccine: What Healthcare Professionals Need to Know](#) (Updated March 7, 2022)
-  [Pfizer-BioNTech COVID-19 Vaccine: What Healthcare Professionals Need to Know](#) (Updated March 7, 2022)

- [COVID-19 Vaccine Webinar Series](#) | CDC: Short 15 -20 minutes. Topics range from routine clinical and vaccine safety information to guidance for on-site clinic vaccination activities and having conversations with vaccine recipients. Each webinar includes self-test practice questions and lists additional resources related to the topic discussed.
- Pfizer Vaccines US Medical Affairs hosts **frequent** Medical Updates & Immunization Site Training for All Healthcare Providers. For a list of training sessions, including links and instructions for registration, visit the <https://www.pfizermedicalinformation.com/en-us/medical-updates>

# COVID-19 Vaccine EUA Fact Sheets

## Health Care Providers

[Pfizer-BioNTech, maroon cap \(6m - 4 years\)](#)

[Pfizer-BioNTech, orange cap \(5 - 11 years\)](#)

[Pfizer-BioNTech, gray cap \(12+ years\)](#)

[Moderna, lite blue border \(12+ years\)](#)

[Moderna, magenta border \(6m - 5 years\)](#)

[Janssen \(J&J\) \(18+ years\)](#)

## Recipients and Caregivers

[Pfizer-BioNTech, maroon cap \(6m - 4 years\)](#)

[Pfizer-BioNTech, orange cap \(5 - 11 years\)](#)

[Pfizer-BioNTech, gray cap \(12+ years\)](#)

[Moderna, lite blue border \(12+ years\)](#)

[Moderna, magenta border \(6m - 5 years\)](#)

[Janssen \(J&J\) \(18+ years\)](#)

# COVID-19 Vaccine Storage and Handling Resources

VDH Resources:

[Receipt and Management of COVID-19 Vaccine](#)

[COVID-19 Vaccine Expiration Date and BUD Guidance](#)

[Vaccine Carrier Borrowing Program](#)

[Vaccine Storage and Handling for Off-site Clinic Guidance](#)

[Temperature Excursion Protocol](#)

CDC/Manufacturer Resources: [U.S. COVID-19 Vaccine Product Information | CDC](#)  
**Storage and Handling Summaries**

# COVID-19 Vaccine Administration Resources

[Vaccine Administration Training](#) | You Call the Shots

[Interim Clinical Considerations for Use of COVID-19 Vaccines](#) | CDC

[COVID-19 Vaccine Interim COVID-19 Immunization Schedule for Ages 5+](#) | CDC

[COVID-19 Vaccine Administration Errors and Deviations](#) | CDC

CDC/Manufacturer Resources : [U.S. COVID-19 Vaccine Product Information](#) | CDC

## Consolidated resources

[Checklist of Current Versions of COVID-19 Vaccination Guidance Tools](#) | IAC: A frequently updated resources with most recent links to EUAs, schedules, checklists, medical orders and CDC summary documents.

[COVID-19 Vaccine: Quick Reference Guide for Healthcare Professionals](#) | CDC: A printable table with basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products.

[Summary Document for Interim Clinical Considerations](#) | CDC: A printable table summarizing the sections found in the full Interim Clinical Considerations page.

## Communication Resources for Healthcare Providers and Staff

### How to Talk with Parents about COVID-19 Vaccination



Tips for Pediatricians, Family Medicine Practitioners, and Other Pediatric Providers

### Talking with Patients about COVID-19 Vaccination



An Introduction to Motivational Interviewing for Healthcare Professionals

### Answering Patients' Questions About COVID-19 Vaccine and Vaccination



Key talking points to prepare yourself for answering common questions

### Talking to Patients with Intellectual and Developmental Disabilities about COVID-19 Vaccination



Tips for Healthcare Providers & Clinical Staff

### How to Address COVID-19 Vaccine Misinformation



Communicating accurate information, responding to gaps, and confronting misinformation

### How to Tailor COVID-19 Information to Your Specific Audience



Understanding your audience, creating messages and materials, and getting feedback

[Talking to Recipients about COVID-19 Vaccination | CDC](#)